The donor in the study has PSP, a neurodegenerative tau-related pathology that may alter ECM composition through increased expression of ECM-modifying enzymes (Bonneh-Barkay and Wiley, 2009) and pro-inflammatory cytokines, and/or altered glycosylation patterns (Moretto et al., 2022). Here, MAPT is linked to supranuclear palsy, progressive, 1.